Total Payments
$20,821
2024 Payments
$4,352
Companies
27
Transactions
270
Medicare Patients
1,406
Medicare Billing
$3.8M
Payment Breakdown by Category
Consulting$8,762 (42.1%)
Food & Beverage$7,341 (35.3%)
Travel$2,066 (9.9%)
Other$2,023 (9.7%)
Education$629.23 (3.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $8,762 | 7 | 42.1% |
| Food and Beverage | $7,341 | 247 | 35.3% |
| Travel and Lodging | $2,066 | 1 | 9.9% |
| Honoraria | $1,400 | 1 | 6.7% |
| Education | $629.23 | 12 | 3.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $383.00 | 1 | 1.8% |
| Grant | $239.52 | 1 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $8,868 | 35 | $0 (2024) |
| Horizon Therapeutics plc | $1,805 | 19 | $0 (2023) |
| Amgen Inc. | $1,682 | 20 | $0 (2024) |
| Janssen Global Services, LLC | $1,500 | 1 | $0 (2020) |
| UCB, Inc. | $1,155 | 47 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $1,093 | 4 | $0 (2024) |
| ABBVIE INC. | $839.98 | 34 | $0 (2024) |
| Lilly USA, LLC | $581.05 | 27 | $0 (2024) |
| Johnson & Johnson Health Care Systems Inc. | $483.68 | 7 | $0 (2024) |
| Celgene Corporation | $428.44 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,352 | 88 | Janssen Biotech, Inc. ($1,187) |
| 2023 | $1,713 | 69 | UCB, Inc. ($384.77) |
| 2022 | $2,856 | 52 | Horizon Therapeutics plc ($1,601) |
| 2021 | $1,457 | 21 | Amgen Inc. ($1,193) |
| 2020 | $6,096 | 5 | Janssen Biotech, Inc. ($4,500) |
| 2019 | $1,024 | 17 | UCB, Inc. ($199.80) |
| 2018 | $609.84 | 8 | Celgene Corporation ($383.00) |
| 2017 | $2,713 | 10 | Janssen Biotech, Inc. ($2,288) |
All Payment Transactions
270 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Radius Health, Inc. | — | Food and Beverage | In-kind items and services | $20.99 | General |
| 12/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $23.38 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $5.10 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $23.64 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $6.11 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $23.55 | General |
| Category: IMMUNOLOGY | ||||||
| 12/06/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $16.38 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/04/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $9.27 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $7.64 | General |
| Category: Immunology | ||||||
| 11/25/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $23.09 | General |
| Category: Immunology | ||||||
| 11/22/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $19.73 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/18/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $94.51 | General |
| 11/16/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $123.59 | General |
| Category: Immunology | ||||||
| 11/15/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $108.62 | General |
| Category: Immunology | ||||||
| 11/14/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $19.08 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/09/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $19.36 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $27.68 | General |
| Category: Immunology | ||||||
| 11/01/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $26.54 | General |
| Category: Immunology | ||||||
| 11/01/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $6.25 | General |
| Category: IMMUNOLOGY | ||||||
| 10/28/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $37.03 | General |
| Category: Immunology | ||||||
| 10/25/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $18.79 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/24/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $25.16 | General |
| Category: Immunology | ||||||
| 10/23/2024 | Sandoz Inc. | HYRIMOZ (Biological) | Food and Beverage | In-kind items and services | $14.80 | General |
| Category: Immunology | ||||||
| 10/21/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $17.72 | General |
| Category: IMMUNOLOGY | ||||||
| 10/19/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological), NUCALA | Food and Beverage | In-kind items and services | $105.55 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 336 | 77,973 | $2.9M | $1.1M |
| 2022 | 12 | 351 | 24,403 | $2.2M | $1.1M |
| 2021 | 12 | 374 | 24,790 | $2.2M | $1.1M |
| 2020 | 9 | 345 | 7,724 | $847,178 | $450,617 |
Total Patients
1,406
Total Services
134,890
Medicare Billing
$3.8M
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9312 | Injection, rituximab, 10 mg | Office | 2023 | 17 | 7,650 | $980,800 | $397,039 | 40.5% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 14 | 8,900 | $773,675 | $299,731 | 38.7% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 13 | 50,760 | $564,720 | $235,721 | 41.7% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 13 | 7,700 | $201,650 | $81,357 | 40.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 55 | 445 | $153,525 | $44,450 | 29.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 18 | 1,800 | $79,380 | $33,173 | 41.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 76 | 141 | $51,230 | $18,710 | 36.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 53 | 72 | $19,440 | $7,049 | 36.3% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 20 | 80 | $15,432 | $4,475 | 29.0% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 26 | 203 | $22,330 | $4,344 | 19.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 16 | 74 | $6,290 | $948.69 | 15.1% |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | Office | 2023 | 15 | 148 | $2,960 | $466.32 | 15.8% |
| J9312 | Injection, rituximab, 10 mg | Office | 2022 | 24 | 10,580 | $1.1M | $623,074 | 55.8% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 12 | 5,625 | $416,250 | $194,894 | 46.8% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2022 | 12 | 5,120 | $384,000 | $145,231 | 37.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 18 | 1,860 | $52,980 | $31,723 | 59.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 49 | 297 | $102,465 | $31,448 | 30.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 80 | 130 | $47,320 | $15,171 | 32.1% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 33 | 307 | $33,770 | $7,171 | 21.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 52 | 76 | $20,520 | $5,975 | 29.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 15 | 68 | $18,585 | $3,277 | 17.6% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 20 | 105 | $8,925 | $1,385 | 15.5% |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | Office | 2022 | 19 | 208 | $4,160 | $693.39 | 16.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 17 | 27 | $1,728 | $269.30 | 15.6% |
| J9312 | Injection, rituximab, 10 mg | Office | 2021 | 23 | 8,940 | $921,060 | $560,118 | 60.8% |
About Dr. Todd Daugherty, M.D
Dr. Todd Daugherty, M.D is a Rheumatology healthcare provider based in Henniker, New Hampshire. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/02/2007. The National Provider Identifier (NPI) number assigned to this provider is 1639390776.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Todd Daugherty, M.D has received a total of $20,821 in payments from pharmaceutical and medical device companies, with $4,352 received in 2024. These payments were reported across 270 transactions from 27 companies. The most common payment nature is "Consulting Fee" ($8,762).
As a Medicare-enrolled provider, Daugherty has provided services to 1,406 Medicare beneficiaries, totaling 134,890 services with total Medicare billing of $3.8M. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Other Specialties Rheumatology
- Location Henniker, NH
- Active Since 05/02/2007
- Last Updated 12/23/2019
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1639390776
Products in Payments
- TREMFYA (Drug) $8,648
- SIMPONI ARIA (Biological) $3,051
- KRYSTEXXA (Biological) $2,019
- Otezla (Drug) $1,612
- Cimzia (Drug) $1,042
- RINVOQ (Biological) $529.53
- TALTZ (Drug) $495.80
- ACTHAR (Biological) $406.12
- ORENCIA (Biological) $282.24
- SAPHNELO (Biological) $248.07
- COSENTYX (Drug) $199.05
- Enbrel (Biological) $190.93
- STELARA (Biological) $188.01
- XELJANZ (Drug) $164.71
- Rituxan (Biological) $157.85
- BENLYSTA (Biological) $146.20
- SKYRIZI (Biological) $142.38
- KEVZARA (Biological) $137.35
- Humira (Biological) $130.24
- Bimzelx (Biological) $112.96
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.